详情页

资源类型：

文章类型：

作者：

Yuankai Shi [1] * ; QingYuan Zhang[2] ; Xiaonan Hong[3] ; Zhen Wang[4] ; Yuhuan Gao[5]

; Liqun Zou[6] ; Hong Cen[7] ; Lin Gui [1] ; Yufu Li [8] ; Jifeng Feng[9] ; Zhao Wang[10] ; Mingzhi Zhang[11] ; Chuan Jin[12] ; Weihua Zhang[13] ; Jianda Hu[14] ; Chengyun Zheng[15] ; Zhendong Zheng[16] ; Liling Zhang[17] ; Shaoshui Chen[18] ; Yunhong Huang[19] ; Yun Tang[6] ; Yajie Gao[20] ; Miaowang Hao[21] ; Xiaoling Li [22] ; Chunkang Chang[23] ; Haiyan Yang[24] ; Hui Wu[25] ; Lida Shen[26] ; Xiaoyan Ke[27] ; Liangming Zhang[28] ; Yaming Xi [29] ; Linhua Yang[30] ; Liangzhi Xie[31] ;

机构： [1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study onAnticancer Molecular Targeted Drugs, Beijing, China [2]Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China [3]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China [4]Department of Hematology, Linyi Cancer Hospital, Linyi, China [5]Department of Hematology, The Fourth Hospital of Hebei Medical University, Hebei Cancer Hospital, Shijiazhuang, China [6]West China Hospital of Sichuan University, Chengdu, China [7]Department of Medical Oncology, Guangxi Medical University Af􀀀liated Tumor Hospital, Nanning, China [8]Department of Hematology, Af􀀀liated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou,China [9]Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China [10]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China [11]Department of Oncology, The First Af􀀀liated Hospital of Zhengzhou University, Zhengzhou, China [12]Department of Medical Oncology, Af􀀀liated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou,China [13]Department of Hematology, First Hospital of Shanxi Medical University, Taiyuan, China [14]Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China [15]Department of Hematology, The Second Hospital of Shandong University, Jinan, China [16]Department of Oncology, General Hospital of Northern Theater Command, Shenyang, China [17]Department of Oncology, Union Hospital af􀀀liated to Tongji Medical College of Huazhong University of Science andTechnology, Wuhan, China [18]Department of Oncology, Binzhou Medical University Hospital, Binzhou, China [19]Department of Lymphoma, The Af􀀀liated Cancer Hospital of Guizhou Medical University, Guiyang, China [20]Department of Oncology, The First Af􀀀liated Hospital of Dalian Medical University, Dalian, China [21]Department of Hematology, Tangdu Hospital, Air Force Medical University, Xi’an, China [22]Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang, China [23]Department of Hematology, Shanghai Jiao Tong University Af􀀀liated Sixth People’s Hospital, Shanghai, China [24]Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang CancerHospital, Hangzhou, China [25]Department of Medical Oncology, Fujian Cancer Hospital, Fuzhou, China [26]Department of Medical Oncology, Yunnan Cancer Hospital, The Third Af􀀀liated Hospital of Kunming Medical University,Yunnan Cancer Center, Kunming, China [27]Department of Hematology, Peking University Third Hospital, Beijing, China [28]Department of Medical Oncology, Yantai Yuhuangding Hospital, Yantai, China [29]Department of Hematology, The First Hospital of Lanzhou University, Lanzhou, China [30]Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China [31]Sinocelltech Ltd., Beijing, China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区血液学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区血液学

JCR分区：

出版当年[2021]版：

Q1 HEMATOLOGY

最新[2024]版：

Q1 HEMATOLOGY

第一作者：

第一作者机构： [1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study onAnticancer Molecular Targeted Drugs, Beijing, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

文献详情